596 related articles for article (PubMed ID: 20237214)
1. Drug pricing and value in oncology.
Danzon PM; Taylor E
Oncologist; 2010; 15 Suppl 1():24-31. PubMed ID: 20237214
[TBL] [Abstract][Full Text] [Related]
2. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
3. Should drug prices be negotiated under part D of Medicare? And if so, how?
Frank RG; Newhouse JP
Health Aff (Millwood); 2008; 27(1):33-43. PubMed ID: 18180478
[TBL] [Abstract][Full Text] [Related]
4. Ethical and value issues in insurance coverage for cancer treatment.
Brock DW
Oncologist; 2010; 15 Suppl 1():36-42. PubMed ID: 20237216
[TBL] [Abstract][Full Text] [Related]
5. European perspective on the costs and cost-effectiveness of cancer therapies.
Drummond MF; Mason AR
J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
[TBL] [Abstract][Full Text] [Related]
6. Medicare program; Medicare prescription drug benefit. Final rule.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
[TBL] [Abstract][Full Text] [Related]
7. Alternative strategies for Medicare payment of outpatient prescription drugs--Part B and beyond.
Danzon PM; Wilensky GR; Means KE
Am J Manag Care; 2005 Mar; 11(3):173-80. PubMed ID: 15786856
[TBL] [Abstract][Full Text] [Related]
8. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
9. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
[TBL] [Abstract][Full Text] [Related]
10. The development of a value based pricing index for new drugs in metastatic colorectal cancer.
Dranitsaris G; Truter I; Lubbe MS
Eur J Cancer; 2011 Jun; 47(9):1299-304. PubMed ID: 21493060
[TBL] [Abstract][Full Text] [Related]
11. Do drug formulary policies reflect evidence of value?
Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
[TBL] [Abstract][Full Text] [Related]
12. Medicare's coverage of colorectal cancer drugs: a case study in evidence development and policy.
Carino T; Williams RD; Colbert AM; Bridger P
Health Aff (Millwood); 2006; 25(5):1231-9. PubMed ID: 16966718
[TBL] [Abstract][Full Text] [Related]
13. Increasing Divergence in Drug Prices Between the United States and Germany After Implementation of Comparative Effectiveness Analysis and Collective Price Negotiations.
Berkemeier F; Whaley C; Robinson JC
J Manag Care Spec Pharm; 2019 Dec; 25(12):1310-1317. PubMed ID: 31778624
[TBL] [Abstract][Full Text] [Related]
14. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
15. Trends in the prescription drug plans delivering the Medicare Part D prescription drug benefit.
Brill JV
Am J Health Syst Pharm; 2007 Aug; 64(15 Suppl 10):S3-6; quiz S21-S23. PubMed ID: 17646551
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy.
Navarro RP; Morrow T; Baran R
Manag Care Interface; 2002 Jul; 15(7):55-62. PubMed ID: 12143298
[TBL] [Abstract][Full Text] [Related]
17. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
18. The strategic interaction between firms and formulary committees: effects on the prices of new drugs.
García-Alonso MD; García-Mariñoso B
J Health Econ; 2008 Mar; 27(2):377-404. PubMed ID: 18276026
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention: drug pricing and mortality: the case of tamoxifen.
Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J
Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680
[TBL] [Abstract][Full Text] [Related]
20. Use of comparative effectiveness research in drug coverage and pricing decisions: a six-country comparison.
Sorenson C
Issue Brief (Commonw Fund); 2010 Jul; 91():1-14. PubMed ID: 20614655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]